Michael Jackson, PhD, MPH

“Group Health gives us nearly unlimited potential to address vaccine effectiveness and safety questions of national and international importance.”

Michael L. Jackson, PhD, MPH

Group Health Research Institute Assistant Investigator


Michael L. Jackson’s research focuses  on understanding how infectious diseases spread, and on designing and evaluating  interventions such as vaccination programs. Dr. Jackson is the Group Health Research Institute (GHRI) principal  investigator for the United States Influenza Vaccine Effectiveness Network.  This Network aims to provide ongoing evaluations of the U.S. influenza  vaccination program. Dr. Jackson uses data from this Network to study influenza  vaccine effectiveness, to estimate the burden of disease caused by influenza,  and to advance the methodology of vaccine effectiveness studies. He also uses  mathematical models to predict the impact of vaccination programs on the spread  of infectious diseases such as Haemophilus  influenza type b (Hib) and Neisseria  meningitidis.

Dr. Jackson is a co-investigator on  the Vaccine Safety Datalink (VSD) Project. The VSD, a collaboration between  nine U.S. managed care organizations and the Centers for Disease Control and  Prevention (CDC), is the world’s premier system for post-licensure studies of  vaccine safety. As a VSD co-investigator, Dr. Jackson leads studies of the  safety of childhood immunizations and develops methods for using managed care  data for vaccine safety studies.

While studying for his PhD at the University of  Washington, Dr. Jackson was a graduate research associate with GHRI from 2002  to 2007, and then a postdoctoral fellow at GHRI from 2007 to 2008. He then  spent two years as an Epidemic Intelligence Service (EIS)  officer with the CDC in Atlanta. As an EIS officer, Dr. Jackson helped lead  investigations of whooping cough outbreaks and of the 2009 influenza pandemic. He  also designed and oversaw an enhanced surveillance system for invasive Hib  disease in the U.S. during the 2008-2009 shortage of Hib vaccines. He returned  to GHRI as an assistant investigator in 2010.

Research interests and experience




Recent publications

Havers F, Thaker S, Clippard JR, Jackson M, Mclean H, Monto AM, Zimmerman RK, Jackson L, Petrie JG, Nowalk MP, Moehling KK, Flannery B, Thompson MG, Fry AM.

Use of influenza antiviral agents by ambulatory care clinicians during the 2012-13 influenza season.

Clin Infect Dis. 2014 Jul 16. pii: ciu422. [Epub ahead of print].

Osterholm MT, Kelley NS, Belongia EA, Jackson LA, Jackson ML.

Reply: Cochrane rearranged.

Vaccine. 2014 Feb 13. pii: S0264-410X(14)00160-1. doi [Epub ahead of print]. PubMed

Jackson ML, Henrikson NB, Grossman DC.

Evaluating Washington State’s Immunization Information System as a research tool.

Academ Pediatr. 2014 Jan 1;14(1):71-6. doi: 10.1016/j.acap.2013.10.002.

Ohmit SE, Thompson MG, Petrie JG, Thaker SN, Jackson ML, Belongia EA, Zimmerman RK, Gaglani M, Lamerato L, Spencer SM, Jackson L, Meece JK, Nowalk MP, Song J, Zervos M, Cheng PY, Rinaldo CR, Clipper L, Shay DK, Piedra P, Monto AS.

Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates.

Clin Infect Dis. 2013 Nov 13 [Epub ahead of print]. PubMed